Corporate Profile

Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for ZB-106 (tibulizumab), ZB-168, and ZB-880 (torudokimab) with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders, including systemic sclerosis and other novel indications with unmet needs.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Upcoming Events

SEC Filings

Post-effective amendment to an S-Type filing

Report of unscheduled material events or corporate event

8-K